Danuglipron
Danuglipron is a small-molecule GLP-1 receptor agonist, formerly under development by Pfizer that, in an oral formulation, was under investigation as a therapy for diabetes mellitus. Initial results from a randomized controlled trial indicated that it reduced weight and improved diabetic control. The most commonly reported adverse events were nausea, diarrhea, and vomiting. However, in April 2025, Pfizer announced it would abandon further development of danuglipron due to unpredictable liver toxicity.